Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.49 |
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | APAF1 | O14727 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772967 | 0.95 | KMT2A (0.46) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2772271 | 0.91 | ALDH1A1 (0.46) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL3476944 | 0.89 | MAPT (0.54) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2772283 | 0.87 | KDM4E (0.47) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2774351 | 0.87 | KDM4E (0.47) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2773495 | 0.87 | LMNA (0.48) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2773620 | 0.87 | CA1 (0.52) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2774112 | 0.86 | LMNA (0.47) | KMT2AMAPTLMNAMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL2791558 | 0.86 | LMNA (0.47) | KMT2AMAPTLMNAMEN1KDM4E | |
| SCHEMBL2771203 | 0.86 | RAD52 (0.43) | KMT2ALMNAMEN1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | claimed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | claimed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | KMT2A 2507/4885MAPT 4555/4885LMNA 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.